Table 3.
Overview of Antibiotic Therapy on Day 3 in the Preprescription Authorization and the Postprescription Review With Feedback Groups
| Therapy | Preprescription (n = 417) | Postprescription (n = 462) | P Value |
|---|---|---|---|
| Antibiotic regimen inappropriatea | 239 (57.3) | 168 (36.4) | <.01 |
| Antibiotic therapy not indicated | 148 (35.5) | 109 (23.6) | <.01 |
| No bacterial infection | 128 (30.7) | 74 (16.0) | <.01 |
| Treatment course completed | 12 (2.9) | 27 (5.8) | .03 |
| Prophylaxis not indicated | 8 (1.9) | 8 (1.7) | 1.0 |
| Antibiotic therapy too broad | 87 (20.9) | 57 (12.3) | <.01 |
| Unnecessary double coverage | 9 (2.2) | 5 (1.1) | .28 |
| Unnecessary MRSA coverage | 27 (6.5) | 17 (3.7) | .06 |
| Unnecessary broad-spectrum, gram-negative coverage | 26 (6.2) | 19 (4.1) | .17 |
| Unnecessary gram-negative coverage | 16 (3.8) | 8 (1.7) | .06 |
| Unnecessary gram-positive coverage | 4 (1.0) | 0 | … |
| Unnecessary anaerobic coverage | 5 (1.2) | 8 (1.7) | .59 |
| Antibiotic therapy too narrow | 3 (0.7) | 0 | … |
| Equally effective but more cost-effective options existed | 1 (0.2) | 2 (0.4) | 1.00 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
aFor antibiotic therapy considered inappropriate, a single reason was selected whenever possible.
bInappropriate regimens are inclusive of any reason in table.